2. Academic Validation
  3. BCMA-targeted immunotherapy for multiple myeloma

BCMA-targeted immunotherapy for multiple myeloma

  • J Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7.
Bo Yu 1,  Tianbo Jiang 2,  Delong Liu 3
Affiliations

Affiliations

  • 1 Department of Medicine, Lincoln Medical Center, Bronx, NY, USA.
  • 2 Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA.
  • 3 Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA. delong_liu@nymc.edu.
PMID: 32943087 DOI: 10.1186/s13045-020-00962-7
Abstract

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.

Keywords

Antibody-drug conjugate; B cell maturation antigen; BCMA; Belantamab mafodotin; Bispecific T cell engager; CAR-T.

Figures
Products